Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Adams

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Nuclear Medicine and Biology|August 12, 2000
Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody moleculesG P Adams, C C Shaller, L L Chappell, et al.
Cancer Research|January 1, 1996
Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptorA R Amoroso, J I Clark, S Litwin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 1995
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptideA J George, F Jamar, M S Tai, et al.
Protein Engineering|March 1, 1995
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptidesJ E McCartney, M S Tai, R M Hudziak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.
British Journal of Cancer|October 9, 2008
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitroM K Robinson, K M Hodge, E Horak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancerS J Knox, M L Goris, M Tempero, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1996
Single-chain Fv radioimmunotargetingJ S Huston, A J George, G P Adams, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Nuclear Medicine and Biology|August 12, 2000
Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody moleculesG P Adams, C C Shaller, L L Chappell, et al.
Cancer Research|January 1, 1996
Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptorA R Amoroso, J I Clark, S Litwin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 1995
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptideA J George, F Jamar, M S Tai, et al.
Protein Engineering|March 1, 1995
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptidesJ E McCartney, M S Tai, R M Hudziak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.
British Journal of Cancer|October 9, 2008
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitroM K Robinson, K M Hodge, E Horak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancerS J Knox, M L Goris, M Tempero, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1996
Single-chain Fv radioimmunotargetingJ S Huston, A J George, G P Adams, et al.
Pageof 15